Recent Finacing
Recent Raise
Heart Metabolics is a biopharma developing therapies for hypertrophic cardiomyopathy and heart failure, advancing lead candidate perhexiline (Phase 2 completed) with FDA orphan designation and an in‑licensed NCE.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
